Study of Varespladib in Patients Hospitalized With Severe COVID-19
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study
designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition
to standard of care, in patients hospitalized with severe COVID-19 caused by SARS-CoV-2.